We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current MRZM market cap is 4.34M. The company's latest EPS is USD -1.4003 and P/E is -0.06.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 197k | 210k | 233k | 646k |
| Operating Income | -1.06M | -5.8M | -8.82M | -37.32M | -34.09M |
| Net Income | -1.06M | -5.85M | -11M | -38.17M | -65.35M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 28.61M | 47.08M | 66M | 38.69M | 22.02M |
| Total Liabilities | 270k | 1.8M | 18.31M | 21.27M | 26.68M |
| Total Equity | 28.34M | 45.29M | 47.69M | 17.42M | -4.66M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -112k | -3.22M | -5.79M | -10.85M | -4.69M |
| Investing | -13k | -149k | N/A | N/A | N/A |
| Financing | 125k | 6.28M | 6.96M | 7.29M | 4.32M |
| Market Cap | 4.34M |
| Price to Earnings Ratio | -0.06 |
| Price to Sales Ratio | 6.52 |
| Price to Cash Ratio | 28.13 |
| Price to Book Ratio | -0.9 |
| Dividend Yield | - |
| Shares Outstanding | 46.67M |
| Average Volume (1 week) | 5k |
| Average Volume (1 Month) | 3.95k |
| 52 Week Change | -67.09% |
| 52 Week High | 0.405 |
| 52 Week Low | 0.05 |
| Spread (Intraday) | 0.13 (99.03%) |
| Company Name | Marizyme Inc (QB) |
| Address |
701 s. carson street carson city, nevada 89701 |
| Website | https://www.marizyme.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
